Skip to main content
Premium Trial:

Request an Annual Quote

Darren Platt, Ian Goodhead, Neil Hall, Douglas Fambrough, Susan Koppy

Darren Platt has left the Department of Energy’s Joint Genome Institute and will join consumer genotyping startup 23andMe as senior director of research on Oct. 1. At JGI, Platt was the head of the informatics department. He wrote the Forge assembly algorithm, which can handle DNA sequence data from different platforms.

Richard Durbin stepped down as the head of informatics of the Wellcome Trust Sanger Institute in January in order to focus on genome-wide resequencing of humans using new sequencing technologies (see feature in this issue). The new head of the informatics division is Tim Hubbard.

Ian Goodhead is joining Neil Hall’s lab at the University of Liverpool as a graduate student. He will be looking at genomic approaches to understanding evolution of parasite virulence and host adaptation, using 454’s GS FLX in addition to other technologies. Goodhead joins the lab from the Wellcome Trust Sanger Institute, where he worked with next-generation sequencing technology (see In Sequence 2/20/2007).
Hall recently opened a new core facility at Liverpool that is equipped with a 454 sequencer (see In Sequence 7/17/2007)

Douglas Fambrough has been promoted to general partner of Oxford Bioscience Partners, the company said last week. He joined the venture capital firm in January 2000 as an associate and became partner in 2005. Prior to OBP, he was a genomic scientist with the Whitehead/MIT Center for Genome Research. He graduated from Cornell University and received a PhD in genetics from the University of California, Berkeley. At OBP, Fambrough was “actively involved” with the company’s investment in Solexa.

Susan Koppy has become a director of Lorus Therapeutics, the company said last week. She has been senior vice president for business and corporate development of Idenix Pharmaceuticals since January 2006. Prior to that, she was vice president of strategy and business development with Applied Biosystems from 2004 until 2005. Before that, she was director of business development for Novartis Pharmaceuticals.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.